Lapatinib Resistance in Patients With Breast Cancer

Part of paid clinical trials in Cleveland, Ohio.

Sponsor
Case Comprehensive Cancer Center
Study ID
NCT00898573
Status
Withdrawn

Conditions

Eligibility Criteria

Sex
ALL
Age
N/A - N/A
Healthy Volunteers
Not accepted

Interventions

  • lapatinib ditosylate — DRUG
  • fluorescence in situ hybridization — GENETIC
  • gene expression analysis — GENETIC
  • mutation analysis — GENETIC
  • polymerase chain reaction — GENETIC
  • reverse transcriptase-polymerase chain reaction — GENETIC
  • cell sorting — OTHER
  • immunohistochemistry staining method — OTHER
  • laboratory biomarker analysis — OTHER

Study Details

RATIONALE: Studying samples of tumor tissue and blood from patients with cancer in the laboratory may help doctors learn more about cancer and the development of drug resistance in patients. PURPOSE: This research study is looking at lapatinib resistance in patients with breast cancer.

Key Dates

Start date
Jul 31, 2008
Status verified
Oct 2015

Study Design

Enrollment
0 participants (actual)

Primary Outcome Measure

Secondary ErbB2 mutations

Locations (9)

Find similar trials in Cleveland, OH

By condition

Related Studies